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Background: The direct comparison of CA19.9, circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) using
endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) has never been performed for the diagnosis of solid pancreatic
tumours (SPTs).
Methods: We included 68 patients with a SPT referred for EUS-FNA. CTCs were analysed using size-based platform and ctDNA
using digital PCR. The sensitivity, specificity, negative and positive predictive values were evaluated for each marker and their
combination.
Results: SPTs corresponded to 58 malignant tumours (52 pancreatic adenocarcinoma (PA) and 6 others) and 10 benign lesions.
The sensitivity and specificity for PA diagnosis were 73% and 88% for EUS-FNA, 67% and 80% for CTC, 65% and 75% for ctDNA
and 79% and 93% for CA19.9, respectively. The positivity of at least 2 markers was associated with a sensitivity and specificity of
78% and 91%, respectively. CtDNA was the only marker associated with overall survival (median 5.2 months for ctDNAþ vs 11.0
months for ctDNA , P¼ 0.01).
Conclusions: CA19.9 alone and in combination with ctDNA and/or CTC analysis may represent an efficient method for diagnosing
PA in patients with SPTs. Further studies including a larger cohort of patients with both malignant and benign lesions will be
necessary to confirm these promising results.
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Pancreatic adenocarcinoma (PA) is the fourth leading cause of
cancer-related death worldwide, with a poor 5-year survival rate of
o10% across all stages. PA represents 90% of pancreatic tumours;
the other tumours are benign lesions with a pseudotumoral form of
chronic pancreatitis or malignant forms such as an endocrine
tumour, haematological malignancy or metastasis (Kamisawa et al,
2016). At presentation, B80% of patients with PA have a locally
advanced or metastatic disease, and histological confirmation is
usually required before palliative chemotherapy and/or radio-
therapy. In this context, endoscopic ultrasound-guided fine needle
aspiration (EUS-FNA) is considered a standard for PA confirma-
tion in patients presenting an isolated pancreatic tumour (ASGE
Standards of Practice Committee et al, 2016), with a sensitivity and
specificity ranging from 78 to 95% and from 75 to 100%,
respectively (Yoshinaga et al, 2011). The procedure needs to be
repeated in B20–30% of cases, leading to a potential delay for
diagnostic confirmation (Tadic et al, 2008).
To date, the carbohydrate antigen CA19.9 (CA19.9), which has
been approved by the FDA for PA management, is the only marker
used in daily practice. Its clinical interest has been intensively
studied, and it has a sensitivity of 70–81% for PA diagnosis (Chan
et al, 2014; Su et al, 2015). The well-known limitation of CA19.9 is
its low specificity due to the presence of elevated levels in non-
malignant situations, such as cholestasis or diabetes mellitus. In
this context, a liquid biopsy based on circulating tumour DNA
(ctDNA) and circulating tumour cells (CTCs), which result from
metastatic or primary tumour release, are considered very
promising to optimise the diagnosis and decision making in PA
patients. CTCs are rare cells that disseminate into the bloodstream,
and their detection is usually performed by a combination of
enrichment and detection methods. Cell-free DNA (cfDNA)
corresponds to all DNA fragments resulting from both normal
and tumour cells, whereas ctDNA harbors specific genetic
alterations from tumour cells (Diaz and Bardelli, 2014). The
detection of ctDNA requires ultrasensitive technologies, including
next-generation sequencing-based or digital PCR-based platforms
with a sensitivity up to 0.01% of the allelic frequency and a
detection rate ranging from 26 to 90% in PA (Bettegowda et al,
2014; Earl et al, 2015; Kinugasa et al, 2015; Sausen et al, 2015;
Takai et al, 2015; Zill et al, 2015; Brychta et al, 2016).
To date, the usefulness of CTC and ctDNA detection has not
been clearly established in PA patients. We previously reported
that CTC detection using the Screencell method had a sensitivity
and specificity of 55% and 100%, respectively, for PA diagnosis
(Iwanicki-Caron et al, 2013). Similar to colorectal cancer, the
ctDNA level seems to be associated with the disease stage and may
have potential prognostic impacts in patients presenting with a PA
(Earl et al, 2015; Kinugasa et al, 2015; Sausen et al, 2015; Takai
et al, 2015).
To the best of our knowledge, the diagnostic value of CA19.9
compared with CTC and circulating DNA, as well as their
combination, has never been evaluated in PA patients. We
conducted a study to investigate their relevance alone or in
combination in patients who underwent EUS-FNA for a pancreatic
solid tumour.
MATERIALS AND METHODS
Patients and sample collection. Patients undergoing EUS-FNA
for the exploration of a solid pancreatic tumour in Rouen
University Hospital from January 2011 to March 2014 were
included after their informed consent. No patients had received
treatment before the EUS-FNA. PA was classified as localised
disease (LD), locally advanced disease (LAD) or metastatic disease
(MD) based on a CT-scan. For each patient, blood samples were
collected into a single EDTA tube (4ml) for CTC analysis and one
heparinised tube (4ml) for CA19.9 and circulating DNA (cDNA)
analysis immediately before the EUS-FNA procedure. The CA19.9,
CTC and cDNA analyses were centralised, and the study was
approved by the institutional review board (Northwest I).
EUS-FNA technique. The EUS-FNA procedures were performed
under general anesthesia by three experimented endoscopists. The
echoendoscopic examination was performed with radial (GF-
UE160-AL5, Olympus, Tokyo, Japan) and/or linear (GF-UC140P-
AL5, Olympus, Tokyo, Japan) echoendoscopes, and cytological
samples were obtained using three back-and-forth passages with
22G needles. The samples was placed in Hank’s solution, fixed in
AFA (absolute alcohol: 50%, 40% formaldehyde: 20%, acetic acid:
5%, and distilled water: 25%) and embedded in paraffin. The slides
were stained with hematoxylin-eosin-safran and analysed by a
pathologist who classified the samples as follows: positive for
malignancy, suspicious for malignancy, negative for malignancy or
benign lesion and non-contributive. In cases of non-contributive
FNA, the histological confirmation was obtained using a second
FNA, biopsy or a surgical procedure according to the clinical
context.
Determination of the KRAS mutational status in tumour
tissue. DNA for the KRAS mutational status determination was
based on the most adequate genetic material when available
(surgical specimen4biopsy4paraffin-embedded section of the cell
blocks obtained from the EUS-FNA). After extraction, genotyping
of KRAS mutations within exon 2 (codons 12 and 13) was
performed using the SNaPshot multiplex assay, which required at
least 5% tumour cells, as previously described (Lamy et al, 2011).
CA 19.9 analysis. CA19.9 was measured on a Kryptor PLC
(B.R.A.H.M.S., Hennigsdorf, Germany) by the immunological
method in the homogeneous phase. The upper limit of the normal
value was 35UIml 1.
Circulating total DNA. cDNA analysis was performed after
centrifuging the peripheral blood samples at 2700 g for 20min at
room temperature and then at 16 000 g for 10min at 4 1C. The
second step was performed before extraction and after the
heparinised plasma sample previously collected for CA19.9
analysis was thawed. DNA was extracted from 0.35 to 1.7ml of
heparinised plasma using the QIamp Circulating Nucleic Acid kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Data regarding the influence of the initial
plasma volume on cDNA analysis are shown in Supplementary
Figures 1–4 and Supplementary Table 1). The sample was
eluted in a final volume of 30 ml and stored at  20 1C.
Quantification of the cfDNA was performed using a fluorometric
method as previously described (Sefrioui et al, 2015a,b). The
concentration was expressed as ngml 1 of plasma using
the following equation: CP¼CExVE/VP, where CE corresponds
to the concentration of extracted cfDNA (ng ml 1), CP corre-
sponds to the concentration of cfDNA in the plasma (ngml 1),
VE corresponds to the elution volume used for the cfDNA
extraction (ml) and VP corresponds to the plasma volume used to
extract the cfDNA (ml). Consequently, the cfDNA concentrations
could be compared between the patients.
Circulating tumour DNA. The detection of ctDNA was based on
KRAS mutations. First, preamplification was performed since this
step was not associated with any qualitative and quantitative
alterations (including mutant allelic fraction) in the dPCR results
compared with those obtained from the original sample (Wang
et al, 2015; Jackson et al, 2016) (Supplementary Figure 5). Thus, a
preamplification using four ng of cfDNA was performed in a final
volume of 25 ml consisting of 12.5 ml of 2X TaqMan genotyping
master mix (Applied Biosystems, Foster City, CA, USA), 0.25 ml of
BRITISH JOURNAL OF CANCER Circulating markers in pancreatic tumour
2 www.bjcancer.com |DOI:10.1038/bjc.2017.250
the primer/probe mixture (Custom TaqMan SNP Genotyping
Assays for c.35G4A detection, Life Technologies, Carlsbad, CA,
USA) and 2ml of heparinase (New England Biolabs, Ipswich, MA,
USA). According to the results of previous runs showing an
inhibitory effect of heparin on preamplification, heparinase was
systematically added to inhibit the action of heparin in the PCR
(Beutler et al, 1990). All runs were performed using the following
thermocycling conditions: 10min at 95 1C, followed by 15 cycles of
15 s at 95 1C and 4min at 60 1C. The droplet-based dPCR (ddPCR)
platform (Qx200 ddPCR system, Bio-Rad, Hercules, CA, USA) was
used for ctDNA detection. A multiplex assay (Bio-Rad, Hercules,
CA, USA) was used to screen the most common KRAS mutations
found in PA (n¼ 7: c.34G4A, c.34G4C, c.34G4T, c.35G4A,
c.35G4C, c.35G4T and c.38G4A). A simplex assay (Life
Technologies, Carlsbad, CA, USA) based on specific KRAS
mutations was also performed to confirm the results of positive
samples obtained using the multiplex assay. The ddPCR conditions
and precisions concerning the limit of detection are described in
Supplementary Materials. Two simplex assays (c.34G4A and
c.34G4C) failed because no amplification could be achieved for
DNA from heparinised plasma. The ddPCR analysis was
performed blindly from clinical data.
Circulating tumour cell analysis. Blood samples were conserved
at room temperature and processed within 3 h of collection. CTC
isolation was performed using the size-based Screencell Cyto
filtration device according to manufacturer’s instructions as
previously reported (Iwanicki-Caron et al, 2013; Kulemann et al,
2015). Briefly, 4ml of the ScreenCell FC filtration buffer was
incubated for 8min with 3ml of blood to fix the target cells and
lyse the red blood cells (RBCs). Then, the mixture was drawn
through the filter by a vacuum tube. Following the filtration of the
fixed cells, an additional 1.6ml of 1 phosphate-buffered saline
was filtered to remove debris from the filter. Cell cytology was
visualised with hematoxylin-eosin-safran staining. Enumeration
and analysis of the structural characterisation of the CTCs was
performed by an experienced cytopathologist blinded to the
histological diagnosis. The cells were classified as ‘positive’ or
‘negative’ for CTC based on cytomorphological features. The cells
were considered positive (i.e., circulating tumour cells) by the
presence of at least four of the following criteria as previously
described (Hofman et al, 2012): anisonucleosis (ratio40.5), nuclei
larger than the calibrated pore size of the membrane (8mm),
irregular nuclei, high nucleo-cytoplasmic ratio, and presence of
three-dimensional sheets (Supplementary Figure 6). Cells were
considered negative (i.e., circulating non-tumour cells) by the
absence of at least four criteria.
Statistical analysis. The sensitivity, specificity, and negative and
positive predictive values for the PA diagnosis were evaluated for
EUS-FNA, which was considered the standard method, and for
each marker. The performance of combinations, based on at least
two positive markers among CA19.9, CTCs and ctDNA, was also
analysed. A CA19.9 value above the normal limit and/or CTCX1
and/or detectable ctDNA based on the circulating multiplex KRAS
analysis were the cut-offs used for the analysis of the combinations.
The prognostic impact was analysed for overall survival (OS) in
PA patients. For the purpose of the study, the diagnosis of
malignant tumours (i.e., PA or other malignant tumours) was
defined either by histological evidence obtained by EUS-FNA and/
or surgical specimens or by clinical outcomes with metastatic
evolution and the CA19.9 serum level rather than 10-fold the
normal value for PA. Benign lesions (i.e., chronic pancreatitis) were
determined by follow-up of 43 years without any evidence of
progression and EUS-FNA classification of the sample as
indeterminate or negative in at least one procedure. The OS was
calculated from the time of EUS-FNA to death from any cause.
Patients were followed until April 30, 2016. The characteristics of
patients and between predefined groups were expressed as
percentages or means±s.d. for continuous variables and were
compared using the Chi-square test, Fisher’s exact test and
Student’s T test as appropriate. Survival curves were calculated
using the Kaplan–Meier method and compared with the log-rank
test. The statistical analyses were calculated using StatView version
5.0 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient characteristics. A total of 68 patients presenting with a
solid pancreatic tumour were included; their characteristics are
listed in Table 1. The diagnosis corresponded to 58 (85%)
malignant tumours (52 PA and 6 other malignant tumours) and
10 (15%) benign lesions (Table 1). For the 52 patients with PA, 13
had a LD, 17 had a LAD and the 22 remaining patients had a MD.
Surgical resection of the tumour was performed in 9 patients,
including 5 with PA, 3 with others malignant tumours (1
pancreatic neuroendocrine tumour (PanNET), 1 renal clear cell
carcinoma metastasis and 1 fibrolamellar hepatocellular carcinoma
with pancreas invasion) and 1 with a benign tumour correspond-
ing to a pseudo-papillary tumour of the pancreas. The follow-up
period was 25 months for all patients (April 2016) after the last
patient was included (March 2014). At the time of the analysis, the
median follow-up was 7.5 months (range 1–64), and 52 (76.5%)
deaths were observed.
EUS-FNA results. A total of 86 EUS-FNA procedures were
performed, including 1 procedure for 52 patients, 2 for 14 patients
and 3 for 2 patients (mean¼ 1.3±0.5). The diagnostic accuracy of
the first EUS-FNA for PA was 76%, corresponding to a sensitivity
and specificity of 73% and 88%, respectively (Table 2). The final
diagnosis was based on EUS-FNA for 50 patients (first EUS-FNA,
n¼ 39; second or third EUS-FNA, n¼ 11), a hepatic or surgical
biopsy for 6 patients, surgical specimens for 9 patients and clinical
outcomes with the CA19.9 level rather than 10-fold the normal
value for the 3 remaining cases. There were two false positive
results for PA, corresponding to one PanNET and one renal clear
cell carcinoma metastasis on a surgical specimen.
CA19.9. CA 19.9 measurements were available for 63/68 (92.6%)
patients, with a median value of 90UIml 1 (range 4–181 761) in
all patients and 174UIml 1 (range 4–181 761) in PA. The mean
CA19.9 concentration was not significantly different in patients
with or without cholestasis (3087±9059 and 3587 ±12 935,
respectively, P¼ 0.92). The mean concentrations were
7435±28 102, 24±35, and 20±11 in PA, other malignant
tumours and benign lesions, respectively (P¼ 0.25). The difference
between the mean and median values was due to the skewed
distribution of the CA19.9 values, with 5 patients presenting
CA19.9 values greater than 10 000UI/ml (13 759; 16 490; 45 106;
64 095 and 181 761UIml 1) in PA group; conversely, the
maximum CA19.9 in the other groups did not exceed 94UIml 1.
The CA19.9 level was greater than the normal value in 79% (38/48)
of the patients with PA malignant tumours, 17% (1/6) of the
patients with non-PA malignant tumours and 0% (0/9) of the
patients with benign lesions (Po0.001). The sensitivity and
specificity of CA19.9 for the PA diagnosis were 79% and 93%,
respectively (Table 2).
According to the liver test, the sensitivity and specificity were
superior for PA diagnosis in patients without cholestasis (81% and
100%, respectively) vs those with cholestasis (74% and 67%,
respectively) (Supplementary Tables 2 and 3). There was no
correlation between the median CA19.9 (X174UI/ml) and the
baseline clinical parameters.
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CTC detection. The analysis was informative for 64/68 samples
(94%), with filtration difficulties for the 4 remaining cases. CTCs
were detected (X1 CTCml 1) in 36/64 samples (56% of the study
population) compared with 33/49 (67%) patients with PA. The
median CTC levels were 1 CTCml 1(range 0–151) vs 4
CTCml 1 (range 0–151) in these two groups, respectively. As
shown in Table 2, the sensitivity and specificity for the PA
diagnosis were 67% and 80%, respectively. There was a trend for
increased CTC detection with tumour stage, with positive CTC
detected in 16/28 (57%) patients with LD/LAD vs 17/21 (81%)
patients with MD (P¼ 0.12) (Supplementary Table 4). There was
no correlation between the presence of CTC or the median CTC
(X4 CTCml 1) and the baseline clinical parameters. There were
three false positive PA results, corresponding to one PanNET and
two benign lesions.
Total and tumour circulating DNA analyses. Quantification of
cfDNA was expressed as ngml 1 of plasma and was successfully
performed in 56 (82%) patients, with a median value of
57.6 ngml 1 (range 12.9–925.3) in all patients and 59.5 ngml 1
Table 2. Overall accuracy of circulating biomarkers in comparison of EUS-FNA for the diagnosis of pancreatic adenocarcinoma
Circulating biomarkers
CTC % (n) ctDNA % (n) CA19.9 % (n)
Combination of three
biomarkers (X2) % (n)
EUS-FNA
% (n)
EUS-
FNAþCA19.9a
% (n)
Sensitivity 67% (33/49) 65% (28/43) 79% (38/48) 78% (31/40) 73% (38/52)b 100% (48/48)
Specificity 80% (12/15) 75% (9/12) 93% (14/15) 91% (10/11) 88% (14/16)c 80% (12/15)
Positive predictive value 92% (33/36) 90% (28/31) 97% (38/39) 97% (31/32) 93% (38/41) 94% (48/51)
Negative predictive value 43% (12/28) 38% (9/24) 58% (14/24) 53% (10/19) 48% (13/27) 100% (12/12)
Accuracy 70% (45/64) 67% (37/55) 83% (52/63) 80% (41/51) 76% (52/68) 95% (60/63)
Abbreviations: CTC¼ circulating tumour cells; ctDNA¼ circulating tumour DNA; EUS-FNA¼Endoscopic ultrasound-guided fine needle aspiration.
aThe performance of EUS-FNAþCA19.9 combination was based on at least 1 positive result among EUS-FNA and CA19.9.
bSuspicious for malignancy were counted as positive for malignancy.
cTwo false positive cases corresponded to clear-cell renal carcinoma and pancreatic neuroendocrine tumour (PanNET) for which the diagnosis will be adjusted retrospectively.
Table 1. Patients characteristics
Characteristics
Total (n¼68)
n (%)
Adenocarcinoma
(n¼52) n (%)
ctDNA,
(omedian)a n
ctDNA,
(Xmedian)a n P value
Age at baseline (years)
Median (range) 66 (18–89) 67 (44–89)
oMedian 34 26 8 13 0.22
XMedian 34 26 13 8
Sex
Female 29 (43) 23 (44) 7 10 0.53
Male 39 (57) 29 (56) 14 11
Histological type
Adenocarcinoma 52 (76) 52 (100) 21 22 _
Benignb 10 (15) _ _ _
Othersc 6 (9) _ _ _
Tumour size (mm)
Median (range) 30 (12.5–70) 30 (12.5–67)
oMedian 34 26 13 6 0.06
XMedian 34 26 8 15
Mean±s.d. 33.5±12.9 34.3±11.8
Tumour location
Head 48 (71) 35 (67) 16 14 0.75
Body 16 (23) 13 (25) 4 5
Tail 4 (6) 4 (8) 1 2
Stage of diseased
Resectable 16 (28) 13 (25) 5 3 0.45
Locally Advanced 18 (31) 17 (33) 8 6
Metastasis 24 (41) 22 (42) 8 12
KRAS mutational status
Mutant – 23 (72)
Wild -Type – 9 (28) NA NA –
Unknown – 20
aApplicable for patients with pancreatic adenocarcinoma.
bIncludes nine chronic pancreatitis nodules and one pseudo-papillary tumour of pancreas.
cIncludes pancreatic neuroendocrine tumour (PanNET) (n¼ 2), chronic myeloid leukaemia (n¼ 1), B-cell lymphoid neoplasm (n¼ 1), renal clear cell carcinoma (n¼ 1), fibrolamellar hepatocellular
carcinoma (n¼ 1).
dApplicable for PA and malignant non-PA tumours.
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(range 12.9–925.3) in PA. The mean cfDNA concentrations were
99.2±137.2 ngml 1 and 59.1±28.4 ngml 1 in patients with
malignant tumours (PA and others) and benign lesions, respec-
tively (P¼ 0.42). The mean cfDNA concentration was not
significantly different according to the PA stage, with 73.8±45.6,
77.2±41.1 and 122.4±44 in the localised, locally advanced and
metastatic diseases, respectively.
A KRAS circulating mutation was detected in 31/55 (56%) cases
with available blood samples, corresponding to a ctDNA median
value of 0.6% allelic frequency (range 0.17–41.1%) in all patients
and 0.75% allelic frequency (range 0.33–41.1%) in PA. The
sensitivity and specificity of ctDNA for the PA diagnosis were 65%
and 75%, respectively (Table 2). There were 3 false positive PA
results, corresponding to 1 PanNET and 2 benign lesions. There
was a significant increase in ctDNA detection associated with
tumour stage, with ctDNA present in 10/23 (43%) patients with
LD/LAD vs 18/20 (90%) patients with MD (P¼ 0.002)
(Supplementary Table 4). Among the 27 PA patients with available
paired plasma and tumour tissue samples, a KRAS mutation was
found in 17/27 (63%) plasma samples. The concordance of the
KRAS mutational status between the tissue and plasma was 19/27
(70.4%) (Table 3). For the three patients with a KRAS mutation in
circulation and a wild-type KRAS status in the tumour tissue, re-
examination of the blade used for determine the KRAS status in the
tumour tissue showed low tumoural cellularity (i.e., o20%). For
the 31 plasma samples in which a KRAS mutation was identified
with the multiplex assay, 23 (74%) were positive using the simplex
assays (Supplementary Table 5) with the following mutational
profiles: c.34G4T (n¼ 1), c.35G4A (n¼ 13), c.35G4T (n¼ 7),
and c.38G4A (n¼ 6). The multiplex and simplex assay results
were significantly correlated (Figures 1 and 2). There was no
correlation between the cfDNA median (X59.5 ngml 1) and the
baseline clinical parameters. However, the presence of ctDNA was
significantly associated with a larger primary tumour size (83% for
tumours X30mm vs 42% for tumours o30mm, P¼ 0.01).
Marker combinations. The combined analysis of three markers
was available in 51 (75%) patients, and 32 (63%) had at least two
positive markers. The sensitivity and specificity for the PA
diagnosis of the combinations were 78% and 91%, respectively
(Table 2). The sensitivity was similar in patients with and without
cholestasis (78% and 79%, respectively), whereas the specificity was
superior in patients with cholestasis (100% vs 86%, respectively).
Table 3. Results of KRAS detection in tumour tissue and
plasma with multiplex analysis
KRAS mutant
(Tissue)
KRAS wild-type
(Tissue)
Total
(Tissue)
KRAS mutant
(Plasma)
14 3 17
KRAS wild-type
(Plasma)
5 5 10
Total (Plasma) 19 8 27
20 000A
B
C
D
Patient 47 (p.G12D)
Multiplex assay
% ctDNA = 24.8%
Patient 63 (p.G12V)
Multiplex assay
% ctDNA = 41.1%
Patient 63 (p.G12V)
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Patient 47 (p.G12D)
Simplex assay
% ctDNA = 24.4%
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Figure 1. Representation of circulating tumour DNA detection with ddPCR for two patients with pancreatic adenocarcinoma and a KRAS
mutation (p.G12D for patient 47 and p.G12V for patient 63). The graphs in (A and C) illustrate the data obtained with multiplex assays, and the
graphs in (B and D) illustrate the data obtained with simplex assays. The blue and green dots represent droplets containing amplified mutant and
wild-type alleles, respectively. The red dots correspond to droplets containing both mutant and wild-type alleles. The gray dots correspond to
wells containing no alleles (no amplification). % circulating tumour DNA represents the fraction of mutant allele/total allele (wild-type
alleleþmutant allele). Abbreviation: ctDNA, circulating tumour DNA.
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Circulating markers and outcomes. The median OS in patients
with PA was 5.6 months (range 0.1–61.9). The median OS was 11.1
months in patients with LD compared with 7.4 months and 2.6
months in patients with LAD and MD, respectively (P¼ 0.006).
Patients with PA and detectable ctDNA had a significantly shorter
OS compared with patients without detectable ctDNA (5.2 months
vs 11 months, respectively, P¼ 0.01) (Figure 3). A high ctDNA
value (above vs below the median) in PA patients was also
significantly associated with a poorer outcome, with a median OS
of 3.9 months vs 7.8 months, respectively (P¼ 0.04) (Figure 3).
The ctDNA analysis showed a decrease in the OS by quartile
repartition (475%, 50–75%, 25–50%, and o25%), with a median
OS of 2.4 months, 6.1 months, 7.4 months and 11 months,
respectively (P¼ 0.0004). There was no correlation between the
other markers and the outcome in patients with PA and other
lesions (Figure 3).
DISCUSSION
Our results suggest that CA19.9 alone and in combination with
ctDNA and CTC analyses may represent a simple and efficient
approach for PA diagnosis in patients presenting with SPTs with a
sensitivity and specificity of their combination in the whole
population of 78% and 91%, vs 73% and 88% for EUS-FNA alone,
respectively. Moreover, considering the sample size for the
subgroup analysis, CA19.9 performance decreased in cases of
cholestasis, whereas the combination of markers remained
relevant, despite the liver test. Moreover, we observed that a high
ctDNA level at presentation may be associated with shorter
survival in these patients. To the best of our knowledge, these
markers have never been investigated together in patients under-
going an EUS-FNA for a solid pancreatic tumour. Because EUS-
FNA may have some limitations, such as the need for general
anesthesia, our results indicate that the analysis of these markers
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Figure 3. Overall survival of patients with pancreatic adenocarcinoma according to circulating biomarkers at baseline. (A) Kaplan–Maier survival
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Figure 2. Comparison of results obtained with the multiplex and
simplex analyses. The graph illustrates the concordance of the allelic
frequency (r2¼ 0.995) between the 23 samples that tested positive in
the multiplex and simplex analyses.
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may provide relevant information for both diagnosis and
prognosis.
KRAS mutations were logically used as targets for ctDNA
detection because KRAS is the most commonly mutated gene in
PA (90%), with a hotspot region (codons 12/13) covering 90% of
KRAS mutations (Forbes et al, 2017). On the basis of a multiplex
assay covering seven mutations in the hotspot region, we found a
detection rate of 65% in PA patients, with an overall concordance
of 70.4% in the subgroup with available paired tissue and blood
samples. The ddPCR method developed in the present study
showed a detection rate that was slightly superior to the rate that
was recently reported (26–63%) (Earl et al, 2015; Kinugasa et al,
2015; Takai et al, 2015). In our work, a preamplification step was
performed to improve mutant fragment DNA recovery (Jackson
et al, 2016). Moreover, several clinical parameters, such as disease
stage and prior treatment (Earl et al, 2015), may be associated with
ctDNA detection (Bettegowda et al, 2014; Takai et al, 2015). In the
present study, approximately 75% of the cases had advanced PA,
although all patients were treatment naı¨ve at the time of analysis.
Finally, the release of different KRAS subclones into the plasma
(Azuara et al, 2012; Visani et al, 2013; Kinugasa et al, 2015) due to
tumour heterogeneity may also interfere with the ddPCR results, as
indicated by our results in which duplicate or triplicate circulating
mutations were detected in three cases. Taken together, these
findings emphasised that ctDNA appeared to be an important
marker in PA patients and that biological, clinical and preanalytical
conditions are key factors involved in its detection. On the basis of
its prognostic impact in our series and in other studies (Kinugasa
et al, 2015; Sausen et al, 2015; Singh et al, 2015; Takai et al, 2015;
Hadano et al, 2016), further prospective studies are needed to
determine the most appropriate conditions for ctDNA detection as
well as its clinical impact in PA patients.
We detected CTCs in 56% of PA patients, which was
concordant with previous reports using size-based enrichment
methods (Khoja et al, 2012; Kulemann et al, 2015; Poruk et al,
2016). The performance of CTC detection may be variable across
techniques, with lower results obtained with immunological
capture methods such as the Cellsearch technology(Kurihara
et al, 2008; Khoja et al, 2012; Bidard et al, 2013), probably due
to the small fraction of CTCs that express epithelial markers, such
as EpCAM, in PA (Grover et al, 2014). As shown by studies based
on sized-based enrichment methods, we did not observe
differences in survival between patients with positive CTC vs
negative CTC results. To date, the prognostic value of CTC in PA
patients remains a subject of debate. Indeed, although some studies
using immunological capture (Kurihara et al, 2008; Bidard et al,
2013) reported a decrease in survival in the presence of CTCs, a
recent work suggested that a subset of CTCs (i.e., epithelial
phenotype) as opposed to all CTCs had a poorer prognostic impact
in PA patients (Poruk et al, 2016). To summarise, our results
suggest that CTC detection may be useful for PA diagnosis,
whereas their detection provides no relevant prognostic
information.
We observed that CA19.9, which has been widely investigated in
pancreatic illness (Winter et al, 2013), was also the most relevant
marker for PA diagnosis, with a sensitivity of 79% and specificity of
93%. Two meta-analyses found similar values, with 79–81%
sensitivity and 82–90% specificity (Ballehaninna and
Chamberlain, 2012; Su et al, 2015). However, the usefulness of
CA19.9 for PA diagnosis is still debated because of its low
specificity. This value is elevated in several conditions, including
chronic pancreatitis or cholestasis. An increase in CA19.9 was
described in 15–20% of chronic pancreatitis without associated-
cholestasis or PA (Nouts et al, 1998; Slesak et al, 2000). Normal
values in the presence of PA have also been reported in 5–10% of
the population due to the lack of Lewis antigen expression. Because
63% of the PA patients in our work presented concomitant
cholestasis at the initial EUS-FNA, the interpretation of the CA19.9
results needs to be taken with caution. Indeed, diagnosis values of
CA19.9 were particularly interesting in patients without cholestasis
(sensitivity and specificity of 81% and 100%, respectively), whereas
the performance decreased in patients with cholestasis (sensitivity
and specificity of 74% and 67%, respectively) (Supplementary
Tables 2 and 3). To overcome this limitation, we analysed the CTC
and ctDNA in combination with CA19.9. The results showed that
the presence of at least two markers was associated with a
sensitivity and specificity of 78% and 91%, respectively. In patients
with cholestasis, the combination improved the diagnosis accuracy
compared with CA19.9 alone (79% vs 73%, respectively)
(Supplementary Table 2). Interestingly, the positive predictive
value of the combination was 97% for PA compared with 93% for
EUS-FNA. In light of these results, we believe that these circulating
makers may be useful for diagnosing PA and that further studies
are needed to evaluate the relevance of their detection alone and as
a complement to EUS-FNA. Indeed, we showed that the
association of EUS-FNA with CA19.9, which was the most
efficient biomarker in our series, was associated with an
increase in sensitivity (100%) but a loss of specificity (80%). The
additional cost of EUS-FNA remains exorbitant compared with the
cost for the analysis of all 3 biomarkers (i.e., o$300). Moreover,
circulating approach could be performed the same day of the
physician’s visit.
The present study has some limitations. First, the patient cohort
included few patients with benign lesions, which limits any
definitive conclusions from these results, and additional larger
studies are needed to confirm our results. The second limitation
concerns the specificity of all three biomarkers, which have been
reported to be associated with other solid tumours such as colon
cancer. For example, increases in CA19.9 have been identified in
gastric, colonic and esophageal adenocarcinoma at rates of 41%,
34% and 22%, respectively (Steinberg, 1990). However, we analysed
these markers in patients presenting an SPT. Pancreatic metastases
represent a very rare etiology among SPT and occur ino2% of all
cases (Harewood and Wiersema, 2002; Varadarajulu et al, 2005;
Uehara et al, 2011). Considering that majority of these SPTs
originate from renal carcinoma (which are exceptionally associated
with increased CA19.9 expression or KRASmutation (DeWitt et al,
2005; Sweeney et al, 2009; Forbes et al, 2017), we think that these
markers are specific in the PA diagnosis for patients with SPTs.
Another limitation concerns the preanalytical conditions (includ-
ing the variable initial plasma volume), which may have affected
the results of the cDNA analysis. Because of this important issue,
we performed subsequent analyses showing that the plasma
volume used for cDNA extraction did not appear to significantly
influence the cDNA (total and tumour) results (see Supplementary
Figures 1–4). Thus, prospective trials will be necessary to clarify the
optimal preanalytical and analytical conditions used for the ctDNA
and CTC analyses in these settings. Finally, we observed an EUS-
FNA sensitivity of 73% in our population. This result is slightly
inferior to previously reported results (Eloubeidi et al, 2003a,b;
Varadarajulu et al, 2005) and may be due in part to our EUS-FNA
process, which was based on 3–4 fine needle passages, whereas
several works reported better results using 5–7 passages (LeBlanc
et al, 2004).
In conclusion, our results indicate that CA19.9 in combination
with CTC and ctDNA analyses represents an interesting alternative
for PA diagnosis in patients with SPTs. Indeed, if individual
analyses of CTC or ctDNA do not appear to be superior to EUS-
FNA for diagnosing PA, a combination of markers seems to be a
more promising approach with higher sensitivity and specificity
than EUS-FNA alone. We also found that ctDNA may reflect the
tumour burden in patients with solid pancreatic tumours.
These results need to be confirmed, and a prospective study is
currently ongoing in our center (NCT02072616) to confirm the
Circulating markers in pancreatic tumour BRITISH JOURNAL OF CANCER
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diagnostic and prognostic values of CA19.9, CTC and ctDNA in
patients with PA.
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